鼻康片联合色甘萘甲那敏治疗过敏性鼻炎的临床研究  

Clinical study on Bikang Tablets combined with sodium cromoglicate,naphazoline hydrochloride and chlorphenamine maleate in treatment of allergic sinusitis

作　　者：李玲 李伟 罗会林 程庆[4] LI Ling;LI Wei;LUO Hui-lin;CHENG Qing(Department of E.N.T.,Wuhan Red Cross Hospital,Wuhan 430015,China;Department of Urology Surgery,Wuhan Red Cross Hospital,Wuhan 430015,China;Department of Anesthesiology,Wuhan Red Cross Hospital,Wuhan 430015,China;Department of Otolaryngology,Union Hospital of Tongji Medical College of Huazhong University of Science and Technology,Wuhan 430000,China)

机构地区：[1]武汉市红十字医院耳鼻咽喉科,湖北武汉430015 [2]武汉市红十字医院泌尿外科,湖北武汉430015 [3]武汉市红十字医院麻醉科,湖北武汉430015 [4]华中科技大学同济医学院附属协和医院耳鼻咽喉科,湖北武汉430000

出　　处：《现代药物与临床》2022年第9期2049-2053,共5页Drugs & Clinic

基　　金：武汉市医学科研项目(WX21B26)。

摘　　要：目的探讨鼻康片联合色甘萘甲那敏治疗过敏性鼻炎的临床疗效。方法回顾性分析2020年10月—2021年10月在武汉市红十字医院治疗的110例过敏性鼻炎患者的临床资料,随机分为对照组和治疗组,每组各55例。对照组给予色甘萘甲那敏鼻喷雾剂,每次两侧鼻孔各喷1下,3~5次/d,每次间隔>3 h;在对照组基础上,治疗组口服鼻康片,5片/次,3次/d。两组患者均连续治疗8周。观察两组患者临床疗效,比较治疗前后两组患者过敏性鼻炎生活质量测评量表(RQLQ)、鼻症状总分表(TNSS)、伴随症状总分(TNNSS)和鼻内镜(MLK)评分,血清白细胞介素-13(IL-13)、白细胞介素-23(IL23)、白细胞介素-27(IL-27)、可溶性血管细胞间黏附分子-1(sICAM-1)、可溶性程序性死亡配体-1(sPD-L1)和可溶性E选择素(sE-selectin)水平,鼻通气功能指标总鼻气道阻力(NAR)、0~5 cm鼻腔容积(NCV)和鼻腔最小横截面积(NMCA)水平。结果治疗后,对照组有效率为81.82%,明显低于治疗组96.36%(P<0.05)。治疗后,两组RQLQ、TNSS、TNNSS和MLK评分均明显改善(P<0.05);两组患者血清IL-13、IL-23、sICAM-1和sE-selectin水平均明显降低,而sPD-L1和IL27水平明显升高(P<0.05);两组0~5 cm NCV、NMCA均明显升高,而NAR均明显降低(P<0.05);且治疗组这些指标较对照组改善更明显(P<0.05)。结论鼻康片联合色甘萘甲那敏鼻喷雾剂治疗过敏性鼻炎可有效改善患者鼻部症状,提高鼻通气,改善血清细胞因子表达,有利于提高患者生活质量。Objective To explore the clinical efficacy of Bikang Tablets combined with sodium cromoglicate,naphazoline hydrochloride and chlorphenamine maleate in treatment of allergic sinusitis.Methods The clinical data of 110 patients with allergic rhinitis treated in Wuhan Red Cross Hospital from October 2020 to October 2021 were analyzed retrospectively,they were randomly divided into control and treatment group,and each had 55 cases.Patients in the control group were administered with Sodium Cromoglicate,Naphazoline hydrochloride and Chlorphenamine Maleate Nasal Spray,one nostril spray at a time,3 to 5 times daily with an interval of more than 3 h.Patients in the treatment group were po administered with Bikang Tablets on the basis of the control group,5 tablets/time,three times daily.Patients in two groups were treated for 8 weeks.After treatment,the clinical evaluation was evaluated,the scores of RQLQ,TNSS,TNNSS and MLK,the levels of serum IL-13,IL-23,sICAM-1,sE-selectin,sPD-L1 and IL-27,and the nasal respiration function indexes of 0—5 cm NCV,NMCA and NAR in two groups before and after treatment were compared.Results After treatment,the effective rate in the control group was 81.82%,which was significantly lower than 96.36%in the treatment group(P<0.05).After treatment,the scores of RQLQ,TNSS,TNNSS and MLK were significantly improved in two groups(P<0.05),the levels of serum IL-13,IL-23,sICAM-1 and sE-selectin were significantly decreased(P<0.05),the levels of sPD-L1 and IL-27 were significantly increased(P<0.05),0—5 cm NCV,NMCA and NAR were significantly increased(P<0.05),and these indexes were most significantly improved in the treatment group(P<0.05).Conclusion Bikang Tablets combined with Sodium Cromoglicate,Naphazoline hydrochloride and Chlorphenamine Maleate Nasal Spray in the treatment of allergic sinusitis can effectively improve the nasal symptoms of patients,the nasal ventilation,improve the expression of serum cytokines,and it is beneficial to improve the quality of life of patients.

关 键 词：鼻康片 色甘萘甲那敏鼻喷雾剂 过敏性鼻炎 鼻通气功能 可溶性血管细胞间黏附分子-1 可溶性程序性死亡配体-1 可溶性E-选择素 总鼻气道阻力 鼻腔最小横截面积 

分 类 号：R976[医药卫生—药品]